Literature DB >> 8644761

The clinical spectrum of early Lyme borreliosis in patients with culture-confirmed erythema migrans.

R B Nadelman1, J Nowakowski, G Forseter, N S Goldberg, S Bittker, D Cooper, M Aguero-Rosenfeld, G P Wormser.   

Abstract

BACKGROUND: The diagnosis of erythema migrans (EM), the characteristic rash of early Lyme borreliosis, is based primarily on its clinical appearance since it often occurs prior to the development of a specific antibody response. Other skin disorders, however, may be confused with EM.
METHODS: Between June 1991 and September 1993, a prospective study was conducted at the Lyme Disease Diagnostic Center of the Westchester County Medical Center to isolate Borrelia burgdorferi systematically from patients with Em, and to characterize the clinical manifestations of patients with culture-documented infection. Skin biopsies and/or needle aspirates of the advancing margin of primary lesions, and blood specimens from adult patients were cultured for B burgdorferi in modified Barbour-Stoenner-Kelly medium at 33 degrees C.
RESULTS: B burgdorferi was recovered from 79 patients (49 [62%] males) ranging in age from 16 to 76 years old (mean, 43 +/- 14 years old). Maximum EM diameter (mean, 16 +/- 10 cm; range, 6-73 cm) was a function of EM duration (mean 6.7 +/- 6.4 days; range, 1-39 days) (correlation coefficient = 0.7; P < 0.001). Twenty (25%) patients had noted a tick bite at the site of the primary lesion a mean of 10 days (range, 1-27 days) before onset. Multiple EM lesions (range, 2-70) were present in 14 (18%) patients. Systemic symptoms were present at the time of culture in 54 patients (68%) including fatigue (54%), arthralgia (44%), myalgia (44%), headache, (42%), fever and/or chills (39%), stiff neck (35%), and anorexia (26%). Thirty-three patients (42%) had at least one objective finding on physical examination in addition to EM, including 18 (23%) with localized lymphadenopathy, 13 (16%) with fever (t > or = 37.8 degrees C), seven (9%) with tender neck flexion, six (8%) with joint tenderness, and 1 each with joint swelling, nuchal rigidity, and facial nerve palsy. No patient had new electrocardiogram evidence of atrioventricular block. Liver function assays were abnormally elevated in 37% of patients. Thirty-four percent of patients were seropositive by enzyme-linked immunosorbent assay at presentation. Most others rapidly seroconverted so that 69 of 78 evaluable patients (88%) were seropositive at some point during the first month after diagnosis.
CONCLUSIONS: We describe the largest group of culture-positive patients with EM from the United States to date. Although systemic symptoms were present in most patients, objective evidence of advanced disease was uncommon. Our patients with culture-confirmed EM were less sick than those described in the days before culture confirmation was possible. The ability to isolate B burgdorferi from lesional skin of large numbers of patients with EM should make culture-positive patients the standard by which to define manifestations of early Lyme borreliosis associated with this rash. Microbiologic documentation of Lyme borreliosis will help delineate the manifestations of this illness, and should form the framework for research directed at pathophysiology, diagnosis, treatment, and prevention.

Entities:  

Mesh:

Year:  1996        PMID: 8644761     DOI: 10.1016/s0002-9343(95)99915-9

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  54 in total

1.  Characterization of Borrelia burgdorferi isolated from erythema migrans lesions: interrelationship of three molecular typing methods.

Authors:  R Iyer; D Liveris; A Adams; J Nowakowski; D McKenna; S Bittker; D Cooper; G P Wormser; I Schwartz
Journal:  J Clin Microbiol       Date:  2001-08       Impact factor: 5.948

2.  Antibiotics for Travelers: What's Good and What's Not.

Authors:  Kathryn N. Suh; Jay S. Keystone
Journal:  Curr Infect Dis Rep       Date:  2004-02       Impact factor: 3.725

3.  Efficacy of an OspA vaccine preparation for prevention of Lyme disease in New York State.

Authors:  G P Wormser; J Nowakowski; R B Nadelman; I Schwartz; D McKenna; D Holmgren; M Aguero-Rosenfeld
Journal:  Infection       Date:  1998 Jul-Aug       Impact factor: 3.553

Review 4.  Laboratory diagnosis of Lyme disease: advances and challenges.

Authors:  Adriana R Marques
Journal:  Infect Dis Clin North Am       Date:  2015-06       Impact factor: 5.982

5.  Toward a better understanding of European lyme neuroborreliosis.

Authors:  Gary P Wormser; John J Halperin
Journal:  Clin Infect Dis       Date:  2013-05-10       Impact factor: 9.079

Review 6.  The Lyme vaccine: a cautionary tale.

Authors:  L E Nigrovic; K M Thompson
Journal:  Epidemiol Infect       Date:  2006-08-08       Impact factor: 2.451

7.  Genetic diversity of Borrelia burgdorferi in lyme disease patients as determined by culture versus direct PCR with clinical specimens.

Authors:  D Liveris; S Varde; R Iyer; S Koenig; S Bittker; D Cooper; D McKenna; J Nowakowski; R B Nadelman; G P Wormser; I Schwartz
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

8.  Detection and molecular typing of Borrelia burgdorferi sensu lato in Ixodes ricinus ticks and in different patient samples from southwest Germany.

Authors:  D Schaarschmidt; R Oehme; P Kimmig; R D Hesch; S Englisch
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

9.  Borrelia burgdorferi stimulates macrophages to secrete higher levels of cytokines and chemokines than Borrelia afzelii or Borrelia garinii.

Authors:  Klemen Strle; Elise E Drouin; Shiqian Shen; Joseph El Khoury; Gail McHugh; Eva Ruzic-Sabljic; Franc Strle; Allen C Steere
Journal:  J Infect Dis       Date:  2009-12-15       Impact factor: 5.226

10.  Identification of three clinically relevant Borrelia burgdorferi sensu lato genospecies by PCR-restriction fragment length polymorphism analysis of 16S-23S ribosomal DNA spacer amplicons.

Authors:  Renate Ranka; Antra Bormane; Kristine Salmina; Viesturs Baumanis
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.